Receive Your Dual CRISPRi & CRISPRa Screening Poster
Whole genome CRISPR screens to understand how your drug works
View the first direct combination of all three approaches (CRISPRko, CRISPRi and CRISPRa) in the context of genome-wide screens to identify components that influence resistance and sensitivity to the standard of care BRAF inhibitor, vemurafenib.
Learn the benefits of:
- Re-purposed CRISPR tools for drug target identification and validation
- Identification of pathway modulators that affect both drug sensitivity and resistance
- Combining the loss and gain-of-function screening to reveal complex gene networks which control drug response
Simply fill in the form to receive your poster!
* Indicates a required field
